# Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

Study · id `cardio:ct-nct06880770` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06880770](<https://clinicaltrials.gov/study/NCT06880770>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06880770

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 288 participants.

## Technical summary

Registry record NCT06880770. Randomized; quadruple masking; primary purpose treatment. Start 2025-04-24 (actual); primary completion 2029-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 288 participants (planned count; ClinicalTrials.gov record NCT06880770, source copy `cardio:ctgov-nct06880770-2026-09-21`, retrieved 2026-10-31)
- Started: 2025-04-24 (actual) (ClinicalTrials.gov record NCT06880770, source copy `cardio:ctgov-nct06880770-2026-09-21`, retrieved 2026-10-31)
- Primary completion: 2029-03 (anticipated) (ClinicalTrials.gov record NCT06880770, source copy `cardio:ctgov-nct06880770-2026-09-21`, retrieved 2026-10-31)
- Completion: 2029-06 (anticipated) (ClinicalTrials.gov record NCT06880770, source copy `cardio:ctgov-nct06880770-2026-09-21`, retrieved 2026-10-31)
- Countries: United States; Argentina; Austria; Belgium; Brazil; Bulgaria; Canada; China; Colombia; Croatia; Czechia; Georgia; Hungary; Israel; Jordan; Latvia; Lithuania; Mexico; Oman; Saudi Arabia; Serbia; Singapore; Slovakia; South Korea; Sweden; United Arab Emirates; United Kingdom (ClinicalTrials.gov record NCT06880770, source copy `cardio:ctgov-nct06880770-2026-09-21`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06880770-2026-09-21`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
- Acronym: SHASTA-5
- Condition: Severe Hypertriglyceridemia
- Intervention (Drug): Plozasiran
- Intervention (Drug): Placebo
- Lead sponsor: Arrowhead Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry lists this organization as the lead sponsor: Arrowhead Pharmaceuticals (`cardio:org-arrowhead-pharmaceuticals`)

## Provenance

Content hash: 47b56fd2858c0382865dd2260558a073d135cd46a4d2ae35e2540c7115071c13
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
